Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Viracta Therapeutics Inc has a consensus price target of $6.17 based on the ratings of 6 analysts. The high is $11 issued by Oppenheimer on May 23, 2024. The low is $3 issued by Leerink Partners on August 16, 2024. The 3 most-recent analyst ratings were released by Leerink Partners, RBC Capital, and Oppenheimer on August 16, 2024, August 15, 2024, and May 23, 2024, respectively. With an average price target of $6 between Leerink Partners, RBC Capital, and Oppenheimer, there's an implied 2533.89% upside for Viracta Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Viracta Therapeutics (NASDAQ:VIRX) was reported by Leerink Partners on August 16, 2024. The analyst firm set a price target for $3.00 expecting VIRX to rise to within 12 months (a possible 1216.94% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Viracta Therapeutics (NASDAQ:VIRX) was provided by Leerink Partners, and Viracta Therapeutics downgraded their market perform rating.
There is no last upgrade for Viracta Therapeutics
The last downgrade for Viracta Therapeutics Inc happened on August 16, 2024 when Leerink Partners changed their price target from $5 to $3 for Viracta Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on August 16, 2024 so you should expect the next rating to be made available sometime around August 16, 2025.
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a downgraded with a price target of $5.00 to $3.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.